tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2024 Oct 8;30(11).
doi: 10.3201/eid3011.240610. Online ahead of print.
Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021-2022
Dongwon Yoon, Kyungyeon Jung, Ju Hwan Kim, Hwa Yeon Ko, Byeol-A Yoon, Ju-Young Shin; CoVaSC Investigators
We conducted a self-controlled case series study to investigate the association between COVID-19 vaccination and facial palsy (FP) in South Korea. We used a large immunization registry linked with the national health information database. We included 44,564,345 patients >18 years of age who received >1 dose of COVID-19 vaccine (BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, or Ad.26.COV2.S) and had an FP diagnosis and corticosteroid prescription within 240 days postvaccination. We compared FP incidence in a risk window (days 1-28) with a control window (the remainder of the 240-day observation period, excluding any risk windows). We found 5,211 patients experienced FP within the risk window and 10,531 experienced FP within the control window. FP risk increased within 28 days postvaccination, primarily after first and second doses and was observed for both mRNA and viral vaccines. Clinicians should carefully assess the FP risk-benefit profile associated with the COVID-19 vaccines and monitor neurologic signs after vaccination.
Keywords: COVID-19; SARS; SARS-CoV-2; South Korea; coronavirus; coronavirus disease; facial palsy; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccines; viruses; zoonoses.
. 2024 Oct 8;30(11).
doi: 10.3201/eid3011.240610. Online ahead of print.
Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021-2022
Dongwon Yoon, Kyungyeon Jung, Ju Hwan Kim, Hwa Yeon Ko, Byeol-A Yoon, Ju-Young Shin; CoVaSC Investigators
- PMID: 39378869
- DOI: 10.3201/eid3011.240610
We conducted a self-controlled case series study to investigate the association between COVID-19 vaccination and facial palsy (FP) in South Korea. We used a large immunization registry linked with the national health information database. We included 44,564,345 patients >18 years of age who received >1 dose of COVID-19 vaccine (BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, or Ad.26.COV2.S) and had an FP diagnosis and corticosteroid prescription within 240 days postvaccination. We compared FP incidence in a risk window (days 1-28) with a control window (the remainder of the 240-day observation period, excluding any risk windows). We found 5,211 patients experienced FP within the risk window and 10,531 experienced FP within the control window. FP risk increased within 28 days postvaccination, primarily after first and second doses and was observed for both mRNA and viral vaccines. Clinicians should carefully assess the FP risk-benefit profile associated with the COVID-19 vaccines and monitor neurologic signs after vaccination.
Keywords: COVID-19; SARS; SARS-CoV-2; South Korea; coronavirus; coronavirus disease; facial palsy; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccines; viruses; zoonoses.